Owkin

About:

Owkin is an AI precision medicine company with a vision to find the right drug for every patient.

Website: http://www.owkin.com

Twitter/X: owkinscience

Top Investors: Sanofi, Bristol-Myers Squibb, Bpifrance, Google Ventures, F-Prime Capital

Description:

Owkin is a French-American startup that uses artificial intelligence to find the right treatment for every patient. Our focus is to use AI to discover and develop better treatments for unmet medical needs, starting with the fight against cancer. They use AI to identify new drug candidates, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets, while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $255 million and became a ‘unicorn’ – a startup valued at more than $1 billion – in November 2021 through a $180 million investment from French biopharma company Sanofi.

Total Funding Amount:

$304M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2016-01-01

Contact Email:

contact(AT)owkin.com

Hub Tags:

Unicorn

Founders:

Gilles Wainrib, Thomas Clozel

Number of Employees:

251-500

Last Funding Date:

2022-06-08

IPO Status:

Private

© 2024 MyAiNote.com